---
title: "Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 | ATHE Stock News"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/297903918.md"
description: "Alterity Therapeutics announced that CEO David Stamler will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on September 11, 2026. The company highlighted its Multiple System Atrophy program during the event."
datetime: "2026-09-03T03:05:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/297903918.md)
  - [en](https://longbridge.com/en/news/297903918.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/297903918.md)
generator: "portal-rs"
---

# Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 | ATHE Stock News

Alterity Therapeutics highlights its Multiple System Atrophy program as it joins a fireside chat at the Cantor Global Healthcare Conference 2026.

See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google

Add on Google

MELBOURNE, Australia and SAN FRANCISCO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026 on Friday, September 11, 2026 at 10:20 a.m. ET in the United States.

A link to the live and archived webcast may be accessed on Alterity Therapeutics website under the Investors section: Events and Presentations. 

**About Alterity Therapeutics Limited** 

Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodegenerative diseases. The Company is focused on developing disease modifying therapies in Multiple System Atrophy (MSA) and related Parkinsonian disorders. Alterity is preparing to initiate a Phase 3 pivotal trial in MSA, a rare and rapidly progressive disease. ATH434, the Company’s lead asset, has demonstrated clinically meaningful efficacy in a randomized, double-blind, placebo-controlled Phase 2 clinical trial in participants with MSA. Alterity has further reported positive data in its open label Phase 2 clinical trial in participants with advanced MSA. In addition, Alterity has a broad drug discovery platform generating patentable chemical compounds to treat the underlying pathology of neurological diseases. The Company is based in Melbourne, Australia, and San Francisco, California, USA. For further information please visit the Company’s website at https://alteritytx.com.

**Authorisation & Additional information**  
This announcement was authorized by David Stamler, CEO of Alterity Therapeutics Limited.

**Contacts:**

**Investors**  
Elyse Shapiro  
ir@alteritytx.com

Remy Bernarda  
Investor Relations Advisory Solutions  
ir@alteritytx.com  
+1 (415) 203-6386

**Media**  
Melissa Tempra  
NWR Communications  
melissa@nwrcommunications.com.au

Casey McDonald  
Tiberend Strategic Advisors, Inc.  
cmcdonald@tiberend.com  
+1 (646) 577-8520

### Related Stocks

- [ATHE.US](https://longbridge.com/en/quote/ATHE.US.md)
- [ATH.AU](https://longbridge.com/en/quote/ATH.AU.md)

## Related News & Research

- [Alterity Therapeutics issues 8,400,000 shares tied to exercised options at A$ 0.5 each](https://longbridge.com/en/news/298298137.md)
- [Alterity Therapeutics Data Presentations Support Advancement of ATH434 into Phase 3 in Multiple System Atrophy | ATHE Stock News](https://longbridge.com/en/news/286903069.md)
- [ServiceNow Stock Trending: Employees Build AI Agents with Nvidia Oversight](https://longbridge.com/en/news/302098781.md)
- [WithTech Wins KRW 3.92 Billion Equipment Supply Contract From SK Hynix](https://longbridge.com/en/news/302041452.md)
- [Billionaires Are Selling These 6 Artificial Intelligence (AI) Stocks. Should You Follow?](https://longbridge.com/en/news/302092492.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**